What is the 13F Pro Quality Score for IBRX?

13F Pro ranks ImmunityBio, Inc. (IBRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IBRX's current score at https://13fpro.ai/research/IBRX (free sign-up required for the full ranking).

Which hedge funds own the most IBRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IBRX include BlackRock,, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IBRX as soon as new 13F filings post.

Where does 13F Pro source IBRX data?

All ImmunityBio, Inc. fundamentals and ownership data come directly from SEC EDGAR. ImmunityBio, Inc. files with the SEC under CIK 1326110. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IBRX in?

ImmunityBio, Inc. (IBRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IBRX research updated on 13F Pro?

IBRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ImmunityBio, Inc.(IBRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1326110 IBRX stock profile & AI dashboard →

13F Pro Quality Score

30.0/100

Rank #2,380 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.9/100

Profitability

2.9/100

Balance Sheet

0.2/100

Earnings Quality

30.0/100

Free Cash Flow

4.6/100

Institutional Flow

79.7/100

Revenue Scale

19.4/100

Dilution Risk

6.1/100

IBRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ImmunityBio, Inc. (IBRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBRX at 30.0/100 on a 32-signal composite quality model, placing it at rank #2,380 of 2,879 stocks — the bottom half of the AI-ranked universe. IBRX scores in the top quartile across revenue growth (99.9), institutional flow (79.7). Areas of concern include balance sheet strength (0.2) and profitability (2.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ImmunityBio, Inc. reports quarterly revenue of $44.2M, net income of $-632.8M, free cash flow of $-77.1M. Top institutional holders of IBRX by reported 13-F value include BlackRock,, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. IBRX trades on the Nasdaq exchange and files with the SEC under CIK 1326110. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImmunityBio, Inc. directly from SEC EDGAR. ImmunityBio, Inc.'s 13F Pro composite quality score has ranged between 8 and 58 since 2021, currently 30.0 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.

✦

Fun facts about ImmunityBio, Inc.

Quirks, history, and lore behind IBRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Southern California · focused on oncology and infectious disease.
2
The Numbers
A small-cap biotech burning through cash as it funds late-stage trials — revenue is minimal and the company has posted hundreds of millions in cumulative losses chasing its pipeline.
3
The History
The company traces its roots to work by Patrick Soon-Shiong, the billionaire physician-entrepreneur who also owned the Los Angeles Times — not a typical biotech origin story.
4
The Secret
Its platform combines cell therapy, antibodies, and cytokines in a multi-pronged approach meant to wake up the immune system and make it attack tumors — sometimes called an anabolic immunotherapy strategy.
5
The Lore
The FDA granted its bladder cancer drug N-803 a Biologics License Application review, marking a potential milestone for a company that has long operated in the shadow of its founder's more famous ventures.
6
The Giveaway
Ticker IBRX, the brainchild of Patrick Soon-Shiong, is betting that harnessing natural killer cells can crack cancers that have stumped everyone else.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$44.2M

Net Income

Q1 2026

$-632.8M

Free Cash Flow

Q1 2026

$-77.1M

D/E Ratio

Q1 2026

0.00

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+668.3% YoY

$113.3MFY 2025

FY21 $934.0KFY23 $622.0KFY24 $14.7MFY25 $113.3M

Net Income

+15.0% YoY

$-351.5MFY 2025

FY21 $-349.8MFY23 $-583.2MFY24 $-413.6MFY25 $-351.5M

Operating Income

+25.6% YoY

$-256.0MFY 2025

FY21 $-330.3MFY23 $-362.3MFY24 $-344.2MFY25 $-256.0M

EPS (Diluted)

+38.7% YoY

$-0.38FY 2025

FY21 $-0.89FY23 $-1.15FY24 $-0.62FY25 $-0.38

Total Assets

+31.1% YoY

$501.9MFY 2025

FY21 $468.9MFY23 $504.5MFY24 $382.9MFY25 $501.9M

Total Debt

+40.3% YoY

$1.8MFY 2025

FY21 —FY23 —FY24 $1.2MFY25 $1.8M

Op. Cash Flow

+22.1% YoY

$-304.9MFY 2025

FY21 $-274.4MFY23 $-366.8MFY24 $-391.2MFY25 $-304.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2017
Revenue	$113.3M +668.3%	$14.7M +2270.6%	$622.0K -33.4%	$934.0K +54.4%	$605.0K +1244.4%	$45.0K
Net Income	$-351.5M +15.0%	$-413.6M +29.1%	$-583.2M -66.7%	$-349.8M -57.7%	$-221.9M -130.1%	$-96.4M
Operating Income	$-256.0M +25.6%	$-344.2M +5.0%	$-362.3M -9.7%	$-330.3M -49.5%	$-220.9M -122.8%	$-99.1M
EPS (Diluted)	$-0.38 +38.7%	$-0.62 +46.1%	$-1.15 -29.2%	$-0.89 -50.8%	$-0.59	—
Total Assets	$501.9M +31.1%	$382.9M -24.1%	$504.5M +7.6%	$468.9M +111.8%	$221.4M -11.6%	$250.4M
Total Debt	$1.8M +40.3%	$1.2M	—	—	—	—
Operating Cash Flow	$-304.9M +22.1%	$-391.2M -6.7%	$-366.8M -33.6%	$-274.4M -59.8%	$-171.7M -252.0%	$-48.8M

AI Insight: IBRX Financial Trends

Revenue surged from $1M to $44M over two years, but massive $633M Q1 2026 loss drove equity deeper negative to -$870M.

• Revenue accelerated from $1M in Q2 2024 to $44M in Q1 2026, showing consistent quarterly growth momentum.

• Operating losses improved from -$99M in Q2 2024 to -$56M in Q3 2025 before deteriorating to -$70M.

• Operating cash flow losses narrowed from -$100M in Q2 2024 to -$69M in Q3 2025.

⚠ Net loss exploded to -$633M in Q1 2026 from -$67M in Q3 2025, driving equity to -$870M.

⚠ Operating cash flow deteriorated to -$75M in Q1 2026 after improving trend through Q3 2025.

AI Insight: IBRX Ratio Trends

Operating margin improved sequentially from -173.5% in Q3 2025 to -157.9% in Q1 2026, though losses remain substantial.

• Operating margin improved from -173.5% in Q3 2025 to -157.9% in Q1 2026, showing gradual loss reduction.

• ROA improved from -92.1% in Q2 2025 to -49.4% in Q4 2025 before data gap.

⚠ TTM operating margin of -185.4% indicates massive ongoing operational losses relative to revenue.

⚠ Data gaps across multiple quarters limit visibility into consistent trend assessment for key profitability metrics.

Get alerted when IBRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ImmunityBio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IBRX

BlackRock, Inc.
$202.1M26,346,443 sh
STATE STREET CORP
$135.8M17,708,103 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$125.2M16,322,844 sh
VANGUARD CAPITAL MANAGEMENT LLC
$116.0M15,127,714 sh
D. E. Shaw & Co., Inc.
$96.4M12,571,597 sh
GEODE CAPITAL MANAGEMENT, LLC
$61.6M8,031,921 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$43.6M5,683,600 sh
GROUP ONE TRADING, L.P.
$43.5M5,665,700 sh
TWO SIGMA INVESTMENTS, LP
$33.6M4,385,500 sh
MORGAN STANLEY
$30.8M4,018,869 sh

Fund	Value	Shares
BlackRock, Inc.	$202.1M	26,346,443
STATE STREET CORP	$135.8M	17,708,103
VANGUARD PORTFOLIO MANAGEMENT LLC	$125.2M	16,322,844
VANGUARD CAPITAL MANAGEMENT LLC	$116.0M	15,127,714
D. E. Shaw & Co., Inc.	$96.4M	12,571,597
GEODE CAPITAL MANAGEMENT, LLC	$61.6M	8,031,921
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$43.6M	5,683,600
GROUP ONE TRADING, L.P.	$43.5M	5,665,700
TWO SIGMA INVESTMENTS, LP	$33.6M	4,385,500
MORGAN STANLEY	$30.8M	4,018,869

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IBRX on your watchlist

Track score changes the day ImmunityBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IBRX a good stock to buy?

13F Pro's AI-powered analysis of ImmunityBio, Inc. (IBRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBRX are available on the IBRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IBRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ImmunityBio, Inc.'s investment landscape.